Evidence map›Paper›PMID 41112038›Full record

ArticleiMeta2025

RRM2-targeted nanocarrier enhances radiofrequency ablation efficacy in hepatocellular carcinoma through ferroptosis amplification and immune remodeling.

Weiliang Hou, Weifeng Hong, Songhua Cai, Dandan Guo, Zhiping Yan, Jinyu Zhu, Yang Shen, Juncheng Wan, Xudong Qu, Wen Zhang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iMeta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. From Metabolites to Mechanisms:Food science & nutrition · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Weiliang HouDepartment of Gastroenterology, Shanghai Institute of Pancreatic Diseases, National Key Laboratory of Immunity and Inflammation, Changhai Clinical Research Unit, Changhai Hospital Naval Medical University Shanghai China.
Weifeng HongDepartment of Radiation Oncology, Zhejiang Cancer Hospital; Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences Hangzhou China.
Songhua CaiDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China.
Dandan GuoFirst Affiliated Hospital Dalian Medical University Dalian China.
Zhiping YanDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Shanghai Institution of Medical Imaging, Shanghai, National Clinical Research Center of Interventional Medicine Fudan University Shanghai China.
Jinyu ZhuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute Peking University Beijing China.
Yang ShenDepartment of Radiation Oncology Zhongshan Hospital Affiliated to Fudan University Shanghai China.
Juncheng WanDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Shanghai Institution of Medical Imaging, Shanghai, National Clinical Research Center of Interventional Medicine Fudan University Shanghai China.
Xudong QuDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Shanghai Institution of Medical Imaging, Shanghai, National Clinical Research Center of Interventional Medicine Fudan University Shanghai China.
Wen ZhangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Shanghai Institution of Medical Imaging, Shanghai, National Clinical Research Center of Interventional Medicine Fudan University Shanghai China.
Runkang ZhaoFirst Affiliated Hospital Dalian Medical University Dalian China.
Zhao XieFirst Affiliated Hospital Dalian Medical University Dalian China.
Zhongji ChenFirst Affiliated Hospital Dalian Medical University Dalian China.
Tong JiangFirst Affiliated Hospital Dalian Medical University Dalian China.
Yaling LinFirst Affiliated Hospital Dalian Medical University Dalian China.
Wenlong JiaHepatic Surgery Center, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Ling WangFirst Affiliated Hospital Dalian Medical University Dalian China.
Zhao HuangHepatic Surgery Center, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Xuexin LiDepartment of General Surgery, The Fourth Affiliated Hospital China Medical University Shenyang China.ORCID https://orcid.org/0000-0001-5824-9720
Bufu TangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Shanghai Institution of Medical Imaging, Shanghai, National Clinical Research Center of Interventional Medicine Fudan University Shanghai China.ORCID https://orcid.org/0000-0003-3525-4433

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is associated with high mortality rates despite the widespread application of radiofrequency ablation (RFA), which has limited therapeutic efficacy as a monotherapy. This study investigated ribonucleotide reductase M2 (

Indexed as

ferroptosishepatocellular carcinomananocarrierradiofrequency ablationribonucleotide reductase M2

Identifiers

PMID41112038
PMCPMC12527986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.